Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results

July 17, 2026 5:02 AM

Citizens analyst Jonathan Wolleben raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $739.00 (from $737.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found